Moderna Stock Is Surging: What's Going On?
Moderna Inc. (NASDAQ: MRNA) shares are popping Thursday, extending a month-long rally that began with a Phase 3 cancer vaccine breakthrough.
Stocks · News reference
Moderna stock has more than doubled after its cancer-vaccine breakthrough. Now investors face the harder question: Can it become an oncology powerhouse?
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Moderna Inc. (NASDAQ: MRNA) shares are popping Thursday, extending a month-long rally that began with a Phase 3 cancer vaccine breakthrough.
Novo Nordisk taps Anthropic AI to speed medicine research, enhance software workflows, and implement responsible data governance standards.
Moderna reported positive Phase III results for its personalized mRNA cancer therapy (intismeran autogene) developed with Merck, showing significant improvements in recurrence-free and distant metastasis-free survival in melanoma patients. The breakthrough validates Moderna's mRNA platform beyond vaccines and opens opportunities across multiple tumor types, while the company simultaneously expands its respiratory vaccine portfolio with RSV, flu, and combination vaccines to reduce COVID-19 dependence.
Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to 51,778.04
Wall Street snapped a two-day losing streak Thursday as oil retreated from its geopolitical spike and the 10-year Treasury yield slipped back below 5%. Chipmakers led the rebound, with Intel, AMD and Micron all posting outsized gains, while gold climbed 2.5% to $4,369 an ounce. The bounce came one day after the Federal Reserve delivered its first interest rate hike since 2023 and signaled at least one more this year.